Theravance Biopharma Inc. (NASDAQ:TBPH)’s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $28.75 and last traded at $27.91, with a volume of 68,415 shares traded. The stock had previously closed at $28.17.

TBPH has been the topic of several research analyst reports. Leerink Swann initiated coverage on shares of Theravance Biopharma in a research note on Thursday, May 12th. They set an “outperform” rating and a $26.00 target price on the stock. Zacks Investment Research upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research note on Tuesday, July 12th. Guggenheim initiated coverage on shares of Theravance Biopharma in a research note on Monday, June 20th. They set a “buy” rating and a $30.00 target price on the stock. Finally, Bank of America Corp. cut shares of Theravance Biopharma from a “neutral” rating to an “underperform” rating in a research note on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Theravance Biopharma has a consensus rating of “Hold” and a consensus price target of $29.00.

The firm’s market cap is $1.35 billion. The firm has a 50-day moving average of $25.30 and a 200 day moving average of $21.36.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($1.05) by $0.01. On average, equities analysts expect that Theravance Biopharma Inc. will post ($4.03) earnings per share for the current fiscal year.

In other news, EVP Bradford J. Shafer sold 49,122 shares of the firm’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $27.46, for a total transaction of $1,348,890.12. Following the transaction, the executive vice president now owns 241,686 shares in the company, valued at $6,636,697.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Brett K. Haumann sold 9,509 shares of the firm’s stock in a transaction on Friday, August 19th. The shares were sold at an average price of $27.97, for a total value of $265,966.73. Following the transaction, the senior vice president now owns 197,391 shares in the company, valued at approximately $5,521,026.27. The disclosure for this sale can be found here.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.